{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Veliparib", "query": { "intervention": "Veliparib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 80, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Veliparib&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T06:18:40.847Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01017640", "title": "Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mitomycin", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2009-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-07-11", "last_synced_at": "2026-09-04T06:18:40.847Z", "location_count": 2, "location_summary": "Georgetown, Kentucky • Columbus, Ohio", "locations": [ { "city": "Georgetown", "state": "Kentucky" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01017640" }, { "nct_id": "NCT00946335", "title": "ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Atypical Teratoid/Rhabdoid Tumor", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Ependymoblastoma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebellar Astrocytoma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Infratentorial Ependymoma", "Childhood Low-grade Cerebellar Astrocytoma", "Childhood Low-grade Cerebral Astrocytoma", "Childhood Medulloepithelioma", "Childhood Mixed Glioma", "Childhood Oligodendroglioma", "Childhood Supratentorial Ependymoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Brain Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Spinal Cord Neoplasm", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma" ], "interventions": [ { "name": "veliparib", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 31, "start_date": "2009-07", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2014-07-09", "last_synced_at": "2026-09-04T06:18:40.847Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00946335" }, { "nct_id": "NCT03061188", "title": "Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Neoplasm", "Aggressive Non-Hodgkin Lymphoma", "Recurrent Solid Neoplasm", "Refractory Mantle Cell Lymphoma", "T-Cell Non-Hodgkin Lymphoma", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2017-05-23", "completion_date": "2020-08-04", "has_results": true, "last_update_posted_date": "2024-06-12", "last_synced_at": "2026-09-04T06:18:40.847Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03061188" }, { "nct_id": "NCT02163694", "title": "A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Veliparib Placebo", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 513, "start_date": "2014-04-08", "completion_date": "2024-01-25", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-09-04T06:18:40.847Z", "location_count": 56, "location_summary": "Gilbert, Arizona • Little Rock, Arkansas • Duarte, California + 48 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02163694" }, { "nct_id": "NCT00588991", "title": "Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Megakaryoblastic Leukemia", "Adult Acute Monoblastic Leukemia", "Adult Acute Monocytic Leukemia", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With Maturation", "Adult Acute Myeloid Leukemia With Minimal Differentiation", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1", "Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A", "Adult Acute Myeloid Leukemia Without Maturation", "Adult Acute Myelomonocytic Leukemia", "Adult Erythroleukemia", "Adult Pure Erythroid Leukemia", "Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive", "Chronic Myelomonocytic Leukemia", "De Novo Myelodysplastic Syndrome", "Essential Thrombocythemia", "Hematopoietic and Lymphoid Cell Neoplasm", "Myelodysplastic Syndrome", "Polycythemia Vera", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndrome" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2008-02-04", "completion_date": "2016-11-16", "has_results": false, "last_update_posted_date": "2025-04-02", "last_synced_at": "2026-09-04T06:18:40.847Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Rochester, Minnesota", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00588991" }, { "nct_id": "NCT01908478", "title": "Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Veliparib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Intensity modulated radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2013-10-02", "completion_date": "2020-07-06", "has_results": false, "last_update_posted_date": "2020-07-15", "last_synced_at": "2026-09-04T06:18:40.847Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01908478" }, { "nct_id": "NCT02032277", "title": "A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 634, "start_date": "2014-04-02", "completion_date": "2020-11-12", "has_results": false, "last_update_posted_date": "2021-01-20", "last_synced_at": "2026-09-04T06:18:40.847Z", "location_count": 61, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 47 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Salinas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02032277" }, { "nct_id": "NCT01264432", "title": "Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm", "Peritoneal Carcinomatosis", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "RADIATION", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2011-01-01", "completion_date": "2016-11-15", "has_results": false, "last_update_posted_date": "2017-11-21", "last_synced_at": "2026-09-04T06:18:40.847Z", "location_count": 2, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01264432" }, { "nct_id": "NCT02106546", "title": "Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Squamous Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Placebo to veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 970, "start_date": "2014-04-10", "completion_date": "2019-11-20", "has_results": false, "last_update_posted_date": "2020-11-17", "last_synced_at": "2026-09-04T06:18:40.847Z", "location_count": 38, "location_summary": "Jonesboro, Arkansas • Los Angeles, California • Aurora, Colorado + 30 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02106546" }, { "nct_id": "NCT01012817", "title": "Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Malignant Solid Neoplasm", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2009-11-03", "completion_date": "2027-03-10", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-04T06:18:40.847Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01012817" } ] }